Loading
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$9.32
+$0.065 · +0.70%
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Latest quote
$9.32
+$0.065 · +0.70%
After-hours
$9.33
+$0.01 · +0.11%
Oct 9, 6:03 PM ET
Regular session · ET · Market data may be delayed.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Day range
Current $9.32
52-week range
Current $9.32
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
52
Mixed
Risk
22
Moderate Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Day range
Current $9.32
52-week range
Current $9.32
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.03B USD | 11.23B USD | 11.3B USD | 10.86B USD | 9.55B USD |
| Cost of goods sold | 3.83B USD | 4.29B USD | 4.34B USD | 4.28B USD | 3.6B USD |
| Gross profit | 6.99B USD | 6.95B USD | 6.96B USD | 6.58B USD | 5.95B USD |
| Research and development | 308.1M USD | 298M USD | 311M USD | 300M USD | 257M USD |
| Selling, general, and administrative | 4.36B USD | 4.33B USD | 4.29B USD | 4.04B USD | 3.79B USD |
| Operating expenses | 4.43B USD | 4.74B USD | 4.97B USD | 4.75B USD | 4.31B USD |
| Interest income | 76.29M USD | 55M USD | 14M USD | 68.98M USD | 13M USD |
| Interest expense | 332.55M USD | 394M USD | 414M USD | 347.36M USD | 16M USD |
| Depreciation and amortization | 352.11M USD | 324M USD | 309M USD | 287M USD | 268M USD |
| Operating income | 2.41B USD | 2.21B USD | 2B USD | 1.83B USD | 1.64B USD |
| Net income | 1.63B USD | 1.44B USD | 1.05B USD | 1.06B USD | 1.39B USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.20
9.44% upsidePrice history unavailable
High $10.20Average $10.20Low $10.20Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Cash distributions grouped by calendar year; partial years are marked.
$0.1764
2025 complete year+70.1% since 2023
2026 partial: $0.198
$0.1037
2,023
$0.1578
2,024
$0.1764
2,025
$0.198
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 14, 2026 | $0.0647Semi-Annual | Aug 14, 2026 | Sep 17, 2026 |
Dividend | Apr 10, 2026 | $0.1333Semi-Annual | Apr 10, 2026 | May 14, 2026 |
Dividend | Aug 15, 2025 | $0.0598Semi-Annual | Aug 15, 2025 | Sep 18, 2025 |
Dividend | Apr 25, 2025 | $0.1166Semi-Annual | Apr 25, 2025 | Jun 5, 2025 |
Dividend | Aug 16, 2024 | $0.0514Semi-Annual | Aug 16, 2024 | Sep 19, 2024 |
Dividend | Mar 14, 2024 | $0.1064Semi-Annual | Mar 15, 2024 | May 16, 2024 |
Ex-dividend Aug 14, 2026
$0.0647
Semi-Annual
Record Aug 14, 2026 · Payment Sep 17, 2026
Ex-dividend Apr 10, 2026
$0.1333
Semi-Annual
Record Apr 10, 2026 · Payment May 14, 2026
Ex-dividend Aug 15, 2025
$0.0598
Semi-Annual
Record Aug 15, 2025 · Payment Sep 18, 2025
Ex-dividend Apr 25, 2025
$0.1166
Semi-Annual
Record Apr 25, 2025 · Payment Jun 5, 2025
Ex-dividend Aug 16, 2024
$0.0514
Semi-Annual
Record Aug 16, 2024 · Payment Sep 19, 2024
Ex-dividend Mar 14, 2024
$0.1064
Semi-Annual
Record Mar 15, 2024 · Payment May 16, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Developed World ex-US ETFSPDW51.09M0.13%40.77B USD0.03%$49.98+0.64%
VanEck Pharmaceutical ETFPPH39M3.80%1.03B USD0.36%$110.49+1.20%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ32.95M2.49%1.3B USD0.48%$35.59+0.57%
Avantis International Equity ETFAVDE8.54M0.04%19.06B USD0.23%$89.80+0.58%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH5.65M0.55%1.04B USD0.13%$28.3551+1.40%
Scharf Global Opportunity ETFGKAT4.36M2.65%163.9M USD0.59%$44.7957+0.66%
ETF Opportunities Trust - AQE Core ETFAQEC4.22M0.70%605.65M USD0.49%$26.02+0.35%
Franklin ClearBridge Enhanced Income ETFYLDE3.95M2.27%171.68M USD0.48%$55.525+0.31%State Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Pharmaceutical ETFPPHPrincipal Exchange-Traded Funds - Principal International Equity ETFPIEQAvantis International Equity ETFAVDEPortfolio Building Block World Pharma and Biotech Index ETFPBPHScharf Global Opportunity ETFGKATETF Opportunities Trust - AQE Core ETFAQECFranklin ClearBridge Enhanced Income ETFYLDEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
